After several share conversions, it is now a wholly-owned enterprise of China top 500 enterprise, Shanghai Fosun Pharma (Group) Co., Ltd., with a registered capital of 654.38+0.2685 million yuan.
Over the years, the company's products sell well in China with excellent quality and high-tech content. It has formed four product series, such as clinical chemical analysis reagent, enzyme-linked immunosorbent assay reagent, immunoturbidimetric analysis reagent and blood gas electrolyte analyzer, and has become one of the most influential in-vitro diagnostic reagent brands in China, with its sales network all over the country and well received by users. At the same time, the technical service centers located in various places are convenient to communicate with users and meet their needs quickly and efficiently.
Fosun Long March currently has more than 200 employees, with a high degree of education accounting for more than 70%. Since its establishment, it has successively won the National Health Industry Advanced Unit Award of the Ministry of Health, Shanghai Advanced Technology Enterprise Certificate, Shanghai High-tech Enterprise, Shanghai Technology-intensive and Knowledge-intensive Foreign-invested Enterprise awarded by Shanghai Science and Technology Commission, Baoshan Enterprise Technology Center awarded by Shanghai Economic and Information Committee, Shanghai University Star Industrialization Project Certificate, and China National Department of United Nations Science and Technology Information Promotion System. At the same time, it has passed GMP certification of US Food and Drug Administration and TUV ISO 13485 quality system certification of EU.
In order to adapt to the rapid development of the company, Fosun Changzheng successively controlled Yaneng Biotechnology (Shenzhen) Co., Ltd., Shanghai Yao Xing Pharmaceutical Technology Development Co., Ltd. and Shanghai Baixing Biotechnology Co., Ltd., and implemented the diagnosis base construction project on 20 1 1, giving full play to the three dominant brands of Changzheng, Yao Xing and Baixing, with a strong R&D.
At present, the company has obtained nearly 100 product production approvals and 10 invention patents. As the only in-vitro diagnostic reagent authorized to diagnose tuberculosis infection in China, the imported T cell spot kit for tuberculosis infection fills the gap in this field in China.
With the increasing improvement of national medical level, the company will increase its market share and become a leading enterprise in the diagnostic industry through continuous independent research and development, introduction of foreign advanced technology and cooperation with Industry-University-Research.